AbbVie reported mixed Q2 2024 results, adding to my concerns of its growth potential. Looking ahead, I see continued pressure for Humira sales and also increasing in-house R&D expenses. These issues ...
Key Insights The projected fair value for Exelon is US$47.24 based on Dividend Discount Model Current share price ...
DouYu International Holdings' estimated fair value is US$10.09 based on Dividend Discount Model. DouYu International Holdings is estimated to be 30% undervalued base ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback